臨床泌尿器科71巻7号

2017年06月発行

特集 去勢抵抗性前立腺癌（CRPC）─Key Questionsに答える

アビラテロンの効果と使い方

著者： 杉元幹史¹

所属機関： ¹香川大学医学部泌尿器科

ページ範囲：P.474 - P.481

文献概要

Key Question
▶ アビラテロンはどのような症例に使用するのが効果的ですか？

Direct Answer

・エンザルタミド投与前に使用するほうが効果的だと考えられます．

・アビラテロン投与後早期のPSA低下率が高いほど，予後が良好だと推測できます．

・肝機能障害や，併用する糖質コルチコイドの有害事象にも注意を払う必要があります．

参考文献

1） Fizazi K, Scher HI, Molina A, et al : Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer : final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 : 983─992, 2012

2） Ryan CJ, Smith MR, de Bono JS, et al : Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 368 : 138─148, 2013

3） Maughan BL, Luber B, Nadal R, et al : Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer : A Retrospective Study. Prostate 77 : 33─40, 2017

4） Benoist GE, Hendriks RJ, Mulders PFA, et al : Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer : Abiraterone Acetate and Enzalutamide. Clin Pharmacokinetics 55 : 1369─1380, 2016

5） Scher HI, Lu D, Schreiber NA, et al : Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol 2 : 1441─1449, 2016

6） Rescigno P, Lorente D, Bianchini D, et al : Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 70 : 724─731, 2016

7） Stockle M, Flaig T, Ohlmann CH, et al : Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate （AA） therapy in patients with metastatic castration-resistant prostate cancer （mCRPC）? An analysis of AA phase 3 trials. Eur Urol Suppl 13 : e864─e864a, 2014

8） Bellmunt J, Kheoh T, Yu MK, et al : Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer : Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol 69 : 924─932, 2016

9） Droz JP, Efstathiou E, Yildirim A, et al : First-line treatment in senior adults with metastatic castration-resistant prostate cancer : A prospective international registry. Urol Oncol 34 : 234.e21─29, 2016

10） Attard G, Sydes MR, Mason MD, et al : Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 66 : 799─802, 2014

11） Li Z, Alyamani M, Li J, et al : Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533 : 547─551, 2016

12） Noonan KL, North S, Bitting RL, et al : Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol Off J Eur Soc Med Oncol 24 : 1802─1807, 2013

13） Loriot Y, Bianchini D, Ileana E, et al : Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide （MDV3100）. Ann Oncol Off J Eur Soc Med Oncol 24 : 1807─1812, 2013

14） Schrader AJ, Boegemann M, Ohlmann CH, et al : Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65 : 30─36, 2014

15） Bianchini D, Lorente D, Rodriguez-Vida A, et al : Antitumour activity of enzalutamide （MDV3100） in patients with metastatic castration-resistant prostate cancer （CRPC） pre-treated with docetaxel and abiraterone. Eur J Cancer 50 : 78─84, 2014

16） Badrising S, van der Noort V, van Oort IM, et al : Clinical activity and tolerability of enzalutamide （MDV3100） in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120 : 968─975, 2014

17） Cheng HH, Nadal R, Gulati R, et al : The effect of prior abiraterone （Abi） use on the activity of enzalutamide （Enza） in men with mCRPC. J Clin Oncol 32 （suppl 4 ; abstr 18）, 2014

18） Azad AA, Eigl BJ, Murray RN, et al : Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 67 : 23─29, 2015